Latest Posts
-
Why smart people stay misaligned
Movies tend to portray executive failure as a dramatic confrontation in the boardroom. In reality, misalignment creeps in slowly. Commercial wants speed. Operations protects reliability. Finance pushes discipline. Regional leaders optimize for local realities while headquarters seeks scale. Each position makes sense on its own. And that is why smart people stay misaligned: they are…
-
Pharma Talks – Interview with Nils Schrader, PhD, Managing Director BIO.North-Rhine-Westfalia (BIO.NRW)
10 March 2026 Question: BIO.NRW sits at the intersection of science, start-ups, industry and policy. In your view, what is still underestimated when it comes to translating excellent science into sustainable biotech companies? Answer: For me, this question has two dimensions. First, what does it actually take to make translation successful? And second, how do…
-
Pharma Talks – Interview with Alan Vanderborght, CEO and founder Kybora
16 December 2025 1. The M&A environment Jens: How would you describe the current state of pharma and biotech M&A? Are we returning to pre-2022 dynamics, or has something fundamentally shifted? Alan: The M&A landscape in biopharma is primarily driven by upcoming losses of exclusivity over the next five to ten years. Big pharma needs…